Meinhard Hahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Meinhard Hahn has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Grischa Toedt
Division of Molecular Genetics (B060), Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D‐69120 Heidelberg, Germany
3 shared publicationsJochen Wilhelm
3 shared publicationsPeter Lichter
Division of Molecular Genetics (B060), Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D‐69120 Heidelberg, Germany
3 shared publicationsCarina Ittrich
Division of Molecular Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany
2 shared publicationsHeidi Kramer
Division of Molecular Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany
2 shared publicationsJoerg Schlingemann
Division of Molecular Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany
2 shared publications
Latest Publications
- Open Access
- 1 June 2006
- Published by Wiley in International Journal of Cancer
- Vol. 119 (4) , 792-800
Identification of novel oligodendroglioma‐associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray‐based expression profiling
Loss of heterozygosity (LOH) on chromosomal arms 1p and 19q is the most common genetic alteration in oligodendroglial tumors and associated with response to radio‐ and chemotherapy as well as favorable prognosis. Using microsatellite analysis, we previously identified the chromosomal regions 1p36.22‐p36.31 and 19q13.3, as candidate tumor suppressor gene regions being commonly deleted in these tumors. To identify genes within these regions that are downregulated in oligodendroglial tumors with LOH 1p/19q, we performed cDNA microarray‐based RNA expression profiling of 35 gliomas with known allelic status on 1p and 19q, including 7 oligodendrogliomas and 8 diffuse astrocytomas of World Health Organization (WHO) grade II, as well as 14 anaplastic oligodendrogliomas and 6 anaplastic oligoastrocytomas of WHO grade III. The microarrays used for expression profiling carried ∼7,000 gene‐specific cDNAs, with complete coverage of the genes located in 1p36.13‐p36.31 and 19q13.2‐q13.33. Microarray analysis identified 8 genes from these regions (MGC4399, SRM, ICMT, RPL18, FTL, ZIN, FLJ10781 and DBP), which all showed significantly lower expression in 1p/19q‐deleted gliomas when compared to gliomas without 1p/19q losses. Quantitative real‐time reverse transcription‐PCR analyses were performed for the MGC4399, ICMT and RPL18 genes and confirmed the microarray findings. In addition, we found that the cytosolic phospholipase A2 (PLA2G4C) gene at 19q13.3 demonstrated significantly lower expression in anaplastic oligodendrogliomas (WHO grade III) when compared to well‐differentiated oligodendrogliomas (WHO grade II). Taken together, our study provides a set of interesting novel candidate genes that may play important roles in the pathogenesis of oligodendroglial tumors.
- 1 June 2006
- Published by Wiley in International Journal of Cancer
- Vol. 119 (4) , 792-800
Open AccessIdentification of novel oligodendroglioma‐associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray‐based expression profiling
Loss of heterozygosity (LOH) on chromosomal arms 1p and 19q is the most common genetic alteration in oligodendroglial tumors and associated with response to radio‐ and chemotherapy as well as favorable prognosis. Using microsatellite analysis, we previously identified the chromosomal regions 1p36.22‐p36.31 and 19q13.3, as candidate tumor suppressor gene regions being commonly deleted in these tumors. To identify genes within these regions that are downregulated in oligodendroglial tumors with LOH 1p/19q, we performed cDNA microarray‐based RNA expression profiling of 35 gliomas with known allelic status on 1p and 19q, including 7 oligodendrogliomas and 8 diffuse astrocytomas of World Health Organization (WHO) grade II, as well as 14 anaplastic oligodendrogliomas and 6 anaplastic oligoastrocytomas of WHO grade III. The microarrays used for expression profiling carried ∼7,000 gene‐specific cDNAs, with complete coverage of the genes located in 1p36.13‐p36.31 and 19q13.2‐q13.33. Microarray analysis identified 8 genes from these regions (MGC4399, SRM, ICMT, RPL18, FTL, ZIN, FLJ10781 and DBP), which all showed significantly lower expression in 1p/19q‐deleted gliomas when compared to gliomas without 1p/19q losses. Quantitative real‐time reverse transcription‐PCR analyses were performed for the MGC4399, ICMT and RPL18 genes and confirmed the microarray findings. In addition, we found that the cytosolic phospholipase A2 (PLA2G4C) gene at 19q13.3 demonstrated significantly lower expression in anaplastic oligodendrogliomas (WHO grade III) when compared to well‐differentiated oligodendrogliomas (WHO grade II). Taken together, our study provides a set of interesting novel candidate genes that may play important roles in the pathogenesis of oligodendroglial tumors.
- 1 August 2005
- Published by Elsevier in Laboratory Investigation
- Vol. 85 (8) , 1024-1039
Patient-based cross-platform comparison of oligonucleotide microarray expression profiles
- 1 August 2005
- Published by Elsevier in Laboratory Investigation
- Vol. 85 (8) , 1024-1039
Patient-based cross-platform comparison of oligonucleotide microarray expression profiles
- Open Access
- 18 February 2005
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 33 (3) , e29
Effective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarrays
Gene expression analysis using microarrays of synthetic long oligonucleotides is limited in that it requires substantial amounts of RNA. To obtain these quantities from minute amounts of starting material, protocols were developed that linearly amplify mRNA by cDNA synthesis and in vitro transcription. Since orientation of the product is antisense (aRNA), it is inapplicable for dye-labelling by reverse transcription and hybridization to sense-oriented oligonucleotide arrays. Here, we introduce a novel protocol in which aRNA labelling is achieved by a combination of two reverse and one forward transcription reactions followed by dye-incorporation using Klenow fragment, generating fluorescent antisense cDNA. We demonstrate high fidelity in arrays using up to 105-fold amplification, starting from 2 ng total RNA. The generated data are highly reproducible and maintain relative gene expression levels between samples. These results demonstrate that our protocol describes an efficient and reliable technique to expand the applicability of oligonucleotide arrays to studies where RNA is the limited source material.
- 18 February 2005
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 33 (3) , e29
Open AccessEffective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarrays
Gene expression analysis using microarrays of synthetic long oligonucleotides is limited in that it requires substantial amounts of RNA. To obtain these quantities from minute amounts of starting material, protocols were developed that linearly amplify mRNA by cDNA synthesis and in vitro transcription. Since orientation of the product is antisense (aRNA), it is inapplicable for dye-labelling by reverse transcription and hybridization to sense-oriented oligonucleotide arrays. Here, we introduce a novel protocol in which aRNA labelling is achieved by a combination of two reverse and one forward transcription reactions followed by dye-incorporation using Klenow fragment, generating fluorescent antisense cDNA. We demonstrate high fidelity in arrays using up to 105-fold amplification, starting from 2 ng total RNA. The generated data are highly reproducible and maintain relative gene expression levels between samples. These results demonstrate that our protocol describes an efficient and reliable technique to expand the applicability of oligonucleotide arrays to studies where RNA is the limited source material.
- 1 January 2004
- Published by Springer Nature
- p. 107-116
HER-2/neu Gene Copy Number Quantified by Real-Time PCR in Cell Lines and Breast Cancer Tissue
- 1 January 2004
- Published by Springer Nature
- p. 107-116
HER-2/neu Gene Copy Number Quantified by Real-Time PCR in Cell Lines and Breast Cancer Tissue